Stroke, Vol 23, 912-916, Copyright © 1992 by American Heart Association
GW Albers
BACKGROUND: Ticlopidine, an antiplatelet agent with a unique mechanism of
action, is now available for clinical use in the United States and Canada.
SUMMARY OF COMMENT: Recently two large randomized trials demonstrated that
ticlopidine can reduce the risk of subsequent stroke in patients presenting
with a transient ischemic attack or stroke. One study found that
ticlopidine was more effective than aspirin for stroke prevention; however,
it was less well tolerated than aspirin and was associated with severe but
reversible neutropenia in almost 1% of patients. CONCLUSIONS: Ticlopidine
is effective for both primary and secondary stroke prevention. It has a
favorable risk/benefit ratio and is a particularly attractive option for
patients who are unable to take aspirin.
ARTICLES
Role of ticlopidine for prevention of stroke
Stanford Stroke Center, Stanford University Medical Center, CA 94305.
This article has been cited by other articles:
![]() |
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119(1_suppl): 300S - 320S. [Full Text] [PDF] |
||||
![]() |
A. Odawara, K. Kikkawa, M. Katoh, H. Toryu, T. Shimazaki, and Y. Sasaki Inhibitory Effects of TA-993, a New 1,5-Benzothiazepine Derivative, on Platelet Aggregation Circ. Res., April 1, 1996; 78(4): 643 - 649. [Abstract] [Full Text] |
||||
![]() |
T. Iwamoto, H. Kubo, and M. Takasaki Platelet Activation in the Cerebral Circulation in Different Subtypes of Ischemic Stroke and Binswanger's Disease Stroke, January 1, 1995; 26(1): 52 - 56. [Abstract] [Full Text] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |